Niti Ayog

Delta Plus Variant Is Not Yet Classified As Variant Of Concern: Dr. Paul

In the context of the public discourse regarding detection of new variants, Member (Health), NITI Aayog, Dr. VK Paul has reminded the public that the newly detected Delta Plus Variant…

View Post

No Need For Immediate Change In COVISHIELD Dosage Interval: Member, NITI Aayog

There have been some media reports, quoting recent studies, that it would be better to shorten the gap between two doses of COVISHIELD vaccine, in light of the variants in…

View Post

Delhi HC Refuses To Stay Covaxin Clinical Trial On Children Aged 2-18; Issues Notice To DCGI, Centre

VK Paul, Member (Health), Niti Aayog on Tuesday informed that Bharat Biotech is all set begin the phase II and III clinical trials for COVID-19 vaccine Covaxin in children in…

View Post

Covishield, Covaxin Are Safest Of COVID-19 Vaccines, Side-Effects Are Negligible: VK Paul

Covishield and Covaxin, the two COVID-19 vaccines which have received Emergency Use Authorisation (EAU) have been tested on thousands of people and side-effects are negligible, Dr VK Paul, Member (Health),…

View Post